01876nas a2200229 4500008004100000245010800041210006900149260001400218300001200232490000700244520116000251653000901411653001901420653001401439653002401453100002901477700002401506700002601530700002901556700002101585856004001606 2024 eng d00aSynergistic Effect of Imperata cylindrica Root Extract and Erlotinib on A549 Lung Cancer Cell Viability0 aSynergistic Effect of Imperata cylindrica Root Extract and Erlot cJune 2024 a656-6590 v163 a

Background: Erlotinib is typically used to treat lung adenocarcinoma and Imperata cylindrica extract has been shown to exert anti-cancer effects in various human cancer cell lines. Therefore, this study evaluated the combined anticancer effects of Imperata cylindrica ethanol root extract and erlotinib on the A549 lung cancer cell line. Method: The A-549 lung cancer cell line was treated with various combinations of 1/2 IC50, 3/8 IC50, 1/4 IC50, and 1/8 IC50 of I.cylindrica root ethanol extract and erlotinib for 48 hours. Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, analyzed and interpreted using CompuSyn software and a normalized isobologram curve. Result: Of the sixteen combinations, eleven combinations acted synergistically, four were additive, and one was in the antagonist zone. Conclusion: The combination of I. cylindrica root ethanol extract and erlotinib act synergistically to decrease A549 lung cancer cell viability, therefore they are potential lung cancer therapeutics.

10aA54910aCell viability10aErlotinib10aImperata cylindrica1 aIndriyanti, Raden, Anita1 aAriyanto, Eko, Fuji1 aUsman, Hermin, Aminah1 aEffendy, Ristaniah, Rose1 aDhianawaty, Diah uhttps://www.phcogj.com/article/2309